sponsored
PatientsVille.com Logo

PatientsVille

Isotretinoin) Medical Research Studies

Up-to-date List of Isotretinoin) Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Isotretinoin) Medical Research Studies

Rank Status Study
1 Recruiting Prevalence of Liver Fibrosis and Progression of Liver Fibrosis
Condition: HIV Infection and Chronic Alanine Aminotransferase Elevation
Intervention: Other: Fibroscan
Outcome Measure: Liverfibrosis
2 Unknown  Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels
Condition: Chronic Hepatitis C
Intervention: Drug: Peg-Interferon alpha2a plus Ribavirin
Outcome Measures: To evaluate the efficacy of treatment and the outcome of treated patients compared with a control group of untreated patients.;   evaluation of liver fibrosis by Fibroscan after 48-72 weeks of inclusion
3 Recruiting Mesenchymal Stem Cells Treat Liver Cirrhosis
Condition: Liver Cirrhosis
Interventions: Drug: Conserved Therapy;   Procedure: Hepatic artery infusion or Intravenous infusion
Outcome Measures: The level of serum alanine aminotransferase (ALT);   The level of serum total bilirubin (TB);   The level of serum prothrombin time (PT);   The level of serum prealbumin(PA);   The level of serum albumin (ALB);   Overall survival;   liver biopsy
4 Recruiting Mediterranean Lifestyle Intervention in Patients With Non-alcoholic Fatty Liver Disease
Conditions: Non-alcoholic Fatty Liver Disease (NAFLD);   Non-alcoholic Steatohepatitis (NASH)
Interventions: Behavioral: Mediterranean lifestyle;   Behavioral: Mediterranean Diet
Outcome Measures: Serum levels of alanine aminotransferase (ALT);   Serum levels of Alanine Aminotransferase (ALT) and gamma-glutamyl transpeptidase (GGT);   Liver stiffness;   Histological disease activity;   Inflammatory and oxidative stress markers
5 Recruiting 68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients
Condition: Lung Cancer
Intervention: Drug: 68Ga-BNOTA-PRGD2
Outcome Measures: Visual and semiquantitative assessment of lesions and biodistribution;   Blood pressure;   Pulse;   Respiration frequency;   Temperature;   Routine blood test;   Routine urine test;   Serum alanine aminotransferase;   Serum albumin;   Serum creatinine;   Adverse events collection
6 Recruiting Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease
Conditions: Non Alcoholic Fatty Liver Disease;   Steatohepatitis;   Hypertriglyceridemia;   Alanine Aminotransferase, Plasma Level of, Quantitative Trait Locus 1
Interventions: Dietary Supplement: Lovaza;   Other: Omega diet
Outcome Measure: reduction in hepatic fat fraction
7 Not yet recruiting Remote Ischemia Precondition (RIPC) for Hepatic Protection in Patients Undergoing Hepatectomy
Condition: Liver Neoplasms
Interventions: Other: Remote ischemia precondition;   Other: None remote ischemia precondition
Outcome Measures: survival rate;   Alanine Aminotransferase (ALT) level in patients' blood;   aspartic transaminase (AST) level in patients' blood;   complications
8 Not yet recruiting Processing Responses of Grains (PRO-Grains) Study
Conditions: Insulin Resistance;   Cardiovascular Disease;   Diabetes
Intervention: Behavioral: Partial feeding study
Outcome Measures: Change from week 0 in peripheral insulin sensitivity (assessed by frequently-sampled oral glucose tolerance test) at week 4;   Change from week 0 in peripheral insulin sensitivity (assessed by frequently-sampled oral glucose tolerance test) at week 8;   Change from week 0 in peripheral insulin sensitivity (assessed by frequently-sampled oral glucose tolerance test) at week 12;   Change from week 0 in hepatic insulin sensitivity (assessed by frequently-sampled oral glucose tolerance test) at week 4;   Change from week 0 in hepatic insulin sensitivity (assessed by frequently-sampled oral glucose tolerance test) at week 8;   Change from week 0 in hepatic insulin sensitivity (assessed by frequently-sampled oral glucose tolerance test) at week 12;   Change from week 0 in fasting glucose at week 4;   Change from week 0 in fasting glucose at week 8;   Change from week 0 in fasting glucose at week 12;   Change from week 0 in fasting insulin at week 4;   Change from week 0 in fasting insulin at week 8;   Change from week 0 in fasting insulin at week 12;   Change from week 0 in blood lipids at week 4;   Change from week 0 in blood lipids at week 8;   Change from week 0 in blood lipids at week 12;   Change from week 0 in high-sensitivity C-reactive protein at week 4;   Change from week 0 in high-sensitivity C-reactive protein at week 8;   Change from week 0 in high-sensitivity C-reactive protein at week 12;   Change from week 0 in plasminogen activator inhibitor-1 (PAI-1) at week 4;   Change from week 0 in plasminogen activator inhibitor-1 (PAI-1) at week 8;   Change from week 0 in plasminogen activator inhibitor-1 (PAI-1) at week 12;   Change from week 0 in Alanine Aminotransferase (ALT) at week 4;   Change from week 0 in Alanine Aminotransferase (ALT) at week 8;   Change from week 0 in Alanine Aminotransferase (ALT) at week 12;   Change from week 0 in serum metabolomics profile at week 4;   Change from week 0 in serum metabolomics profile at week 8;   Change from week 0 in serum metabolomics profile at week 12;   Change from week 0 in blood pressure at week 4;   Change from week 0 in blood pressure at week 8;   Change from week 0 in blood pressure at week 12;   Change from week 0 in waist circumference at week 4;   Change from week 0 in waist circumference at week 8;   Change from week 0 in waist circumference at week 12;   Change from week 0 in arterial stiffness (assessed by carotid-femoral pulse wave velocity) at week 4;   Change from week 0 in arterial stiffness (assessed by carotid-femoral pulse wave velocity) at week 8;   Change from week 0 in arterial stiffness (assessed by carotid-femoral pulse wave velocity) at week 12;   Change from week 0 in gut microbiome composition (16s rRNA sequencing) and fecal short chain fatty acids at week 4;   Change from week 0 in gut microbiome composition (16s rRNA sequencing) and fecal short chain fatty acids at week 8;   Change from week 0 in gut microbiome composition (16s rRNA sequencing) and fecal short chain fatty acids at week 12;   Change from week 0 in ratings of hunger and satiation at week 4;   Change from week 0 in ratings of hunger and satiation at week 8;   Change from week 0 in ratings of hunger and satiation at week 12;   Change from week 0 in ratings of palatability and acceptability (gastrointestinal symptoms) at week 4;   Change from week 0 in ratings of palatability and acceptability (gastrointestinal symptoms) at week 8;   Change from week 0 in ratings of palatability and acceptability (gastrointestinal symptoms) at week 12;   Change from week 0 in body weight at week 4;   Change from week 0 in body weight at week 8;   Change from week 0 in body weight at week 12;   Change from week 0 in dietary intake at week 4;   Change from week 0 in dietary intake at week 8;   Change from week 0 in dietary intake at week 12;   Change from week 0 in physical activity (assessed by accelerometry) at week 4;   Change from week 0 in physical activity (assessed by accelerometry) at week 8;   Change from week 0 in physical activity (assessed by accelerometry) at week 12
9 Recruiting Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis
Condition: Autoimmune Hepatitis
Interventions: Other: conventional plus UC-MSC treatment;   Other: Conventional plus placebo treatment
Outcome Measures: Liver Histology change;   Serum alanine aminotransferase (ALT);   Serum AST;   Serum Tbil;   Serum immunoglobulin G (IgG);   Serum γ-globulin;   MELD score;   Number of participants with treatment side effects;   Number of participants with improvement of clinical symptoms
10 Recruiting Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions
Conditions: Human Immunodeficiency Virus;   Hepatitis B, Chronic;   Hepatitis C, Chronic
Intervention: Drug: antiretroviral drugs
Outcome Measures: Incidence of grade 3 or 4 transaminase elevations;   Incidence of grade 3 or 4 bilirubin elevations;   Percentage of patients with undetectable HIV RNA at the end of follow-up;   CD4 cell count at the end of follow-up
11 Recruiting Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B
Condition: Hepatitis B
Interventions: Drug: Tenofovir;   Drug: Peginterferon-alfa 2a and tenofovir
Outcome Measures: Hepatitis B surface antigen (HBsAg) loss;   Cumulative HBsAg loss;   Serious Adverse Events;   Adverse events;   Hepatitis B e antigen (HBeAg) loss;   HBeAg loss;   HBsAg seroconversion;   HBeAg seroconversion;   Normalization of Alanine Transaminase(ALT) levels;   HBV DNA <1000 IU/mL;   HBV DNA <20 IU/mL(Lower limit of quantification [LLOQ]) of COBAS Ampliprep/COBAS TaqMan HBV v2.0 test);   Absence of detectable antiviral drug-resistance HBV mutations;   Sustained HBV DNA <1000 IU/mL
12 Recruiting An Observational Cohort Study Evaluating Fatty Liver Disease and Liver Fibrosis in Moderate to Severe Psoriasis
Conditions: Psoriasis Chronic;   Liver Fibrosis;   Fatty Liver;   Non-alcoholic Fatty Liver Disease
Intervention: Device: Transient elastography
Outcome Measures: Number of participants with liver fibrosis.;   Number of participants with fatty liver disease diagnosed by ultrasound
13 Recruiting The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients
Conditions: Chronic Hepatitis;   Chronic Hepatitis C;   Chronic Alcoholic Hepatitis
Intervention: Drug: High dose vitamin C
Outcome Measures: The change of serum Alanine Aminotransferase level;   The change of serum interleukin 22 level
14 Not yet recruiting An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population
Conditions: Mild and Moderate Alzheimer's Disease;   Cognitively Healthy People
Intervention:
Outcome Measures: Uridine;   Serum Phospholipids and Fatty Acid Profile;   Red Blood Cell Phospholipids and fatty acid profile;   Plasma polar lipid profile;   Choline;   Homocysteine;   Vitamin B6;   Folate;   Vitamin B12;   Selenium;   Vitamin E;   Vitamin D;   HbA1C  (haemoglobin A1C );   Liver Function - Alanine Aminotransferase and Aspartate Aminotransferase;   Kidney function - Creatinine;   Inflammatory marker
15 Recruiting Hepatitis B Research Network Adult Cohort Study
Condition: Hepatitis B
Intervention:
Outcome Measures: Hepatitis Exacerbation marked by Alanine Aminotransferase (ALT) Flare;   Antigen loss: e and s;   Cirrhosis;   Hepatic decompensation;   Hepatocellular carcinoma (HCC);   Death;   Liver transplantation
16 Not yet recruiting Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA Nat-B env;   Biological: DNA CON-S env;   Biological: DNA Mosaic env;   Biological: MVA-CMDR;   Biological: Placebo for DNA Nat-B env;   Biological: Placebo for DNA CON-S env;   Biological: Placebo for DNA Mosaic env;   Biological: Placebo for MVA-CMDR
Outcome Measures: Frequency of local and systemic injection site reactogenicity signs and symptoms for each type of vaccine;   Severity of local and systemic injection site reactogenicity signs and symptoms for each type of vaccine;   Frequency of adverse events (AEs);   Laboratory measure of safety: measurement of white blood cells (WBC);   Laboratory measure of safety: measurement of neutrophils;   Laboratory measure of safety: measurement of lymphocytes;   Laboratory measure of safety: measurement of hemoglobin;   Laboratory measure of safety: measurement of platelets;   Laboratory measure of safety: measurement of Alanine Aminotransferase (ALT);   Laboratory measure of safety: measurement of aspartate aminotransferase (AST);   Laboratory measure of safety: measurement of alkaline phosphatase;   Laboratory measure of safety: measurement of creatinine;   Number of participants with early discontinuation of vaccinations and reason for discontinuation;   Response rate of CD4 T-cell responses 2 weeks after the last DNA vaccination;   Total magnitude of CD4 T-cell responses 2 weeks after the last DNA vaccination;   Response rate of CD8 T-cell responses 2 weeks after the last DNA vaccination;   Total magnitude of CD8 T-cell responses 2 weeks after the last DNA vaccination;   Breadth of CD4 T-cell responses determined by epitope mapping, 2 weeks after the last DNA vaccination;   Breadth of CD8 T-cell responses determined by epitope mapping, 2 weeks after the last DNA vaccination;   Response rate of CD4 T-cell responses 2 weeks after each MVA vaccination;   Total magnitude of CD4 T-cell responses 2 weeks after each MVA vaccination;   Response rate of CD8 T-cell responses 2 weeks after each MVA vaccination;   Total magnitude of CD8 T-cell responses 2 weeks after each MVA vaccination;   Breadth of CD4 T-cell responses determined by epitope mapping, 2 weeks after MVA vaccination;   Breadth of CD8 T-cell responses determined by epitope mapping, 2 weeks after MVA vaccination;   Magnitude of HIV-specific binding immunoglobulin G (IgG) Env antibody (Ab) responses 2 weeks after the last MVA vaccination;   Breadth of HIV-specific binding IgG Env Ab responses 2 weeks after the last MVA vaccination;   Magnitude of HIV-specific binding immunoglobulin A (IgA) Env Ab responses 2 weeks after the last MVA vaccination;   Breadth of HIV-specific binding IgA Env Ab responses 2 weeks after the last MVA vaccination;   Magnitude of serum neutralizing antibodies (nAbs) to a panel of standardized HIV-1 isolates;   Breadth of serum nAbs to a panel of standardized HIV-1 isolates
17 Recruiting Treatment of Non-alcoholic Steatohepatitis (NASH) Patients With Vitamin D
Condition: Non-alcoholic Steatohepatitis (NASH)
Interventions: Drug: Vitamin D3;   Drug: Placebo
Outcome Measure: Change from Baseline in serum Alanine Aminotransferase levels at week 48
18 Not yet recruiting Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
Conditions: Hepatitis C, Chronic;   HIV Infection
Interventions: Drug: Raltegravir;   Drug: Efavirenz
Outcome Measures: Rates of Grade 2 and higher Alanine Aminotransferase (ALT) elevations;   Plasma HIV RNA </= 150 copies/mL by the Abbot M2000 platform;   Change in CD4 count;   Time to death and/or occurrence of new or recurrent AIDS-defining events;   Changes in fasting blood glucose and cholesterol measures;   Changes in monocyte and T cell immune activation;   Neurocognitive function
19 Recruiting Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: AIDSVAX B/E Vaccine;   Biological: DNA-HIV-PT123 Vaccine;   Biological: Placebo for DNA-HIV-PT123;   Biological: Placebo for AIDSVAX B/E
Outcome Measures: Frequency of local and systemic reactogenicity signs and symptoms;   Laboratory measure of safety: measurement of complete blood count (CBC);   Laboratory measure of safety: measurement of Alanine Aminotransferase (ALT);   Laboratory measure of safety: measurement of creatinine;   Frequency of adverse events (AEs);   Frequency of serious adverse events (SAEs);   HIV-specific binding antibody (Ab) response as assessed by binding Ab multiplex assay;   Response rate and magnitude of CD4 T cell responses as assessed by intracellular cytokine staining (ICS) assays;   Response rate and magnitude of CD8 T cell responses as assessed by ICS assays;   Neutralizing antibody (nAb) magnitude and breadth against tier 1 and tier 2 HIV-1 isolates as assessed by area under the magnitude-breadth curves;   Measurement of HIV-specific Ab and T-cell responses
20 Recruiting HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)
Condition: HIV
Intervention: Drug: FTC/TDF
Outcome Measures: Initiation of PrEP;   Adherence to PrEP;   Adverse events;   STIs;   Changes in sexual risk-taking behavior;   Initiate or decline PrEP;   Incident HIV-seroconversions/characteristics;   Participant perception of care and referral plan

These studies may lead to new treatments and are adding insight into Isotretinoin) etiology and treatment.

A major focus of Isotretinoin) research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Isotretinoin)